Core Viewpoint - The introduction of the standardized domestic formulation Fuli Mei® marks a significant shift in the treatment of melasma, addressing the long-standing issue of "having standards but no standard drugs" in the domestic market [1][2]. Group 1: Clinical Significance - The Kligman triple therapy, consisting of hydroquinone, retinoic acid, and corticosteroids, is recognized as the "gold standard" for treating melasma, supported by extensive clinical evidence and consensus [1]. - Fuli Mei® is the first standardized compound formulation developed strictly according to this gold standard, fulfilling a critical clinical need for reliable treatment tools [1][2]. Group 2: Quality and Efficacy - The emergence of standardized domestic formulations like Fuli Mei® provides stable and convenient tools for physicians, addressing clinical practice pain points [2]. - Clinical research indicates that after 8 weeks of treatment, Fuli Mei® shows a higher efficacy rate compared to historical data of the original drug Tri-Luma, with a lower incidence of adverse reactions, demonstrating dual advantages in efficacy and safety [2]. Group 3: Industry Development - The entry of Fuli Mei® signifies a shift in the Chinese pharmaceutical industry towards quality-driven development, moving from a "follower" to a phase focused on "quality dialogue" and alignment with international standards [2]. - The accessibility of medications is enhanced through internet healthcare platforms, allowing prescription drugs like Fuli Mei® to reach patients more conveniently, promoting a standardized management model for chronic skin diseases [2]. Group 4: Long-term Impact - The ultimate value of this path will be validated by the long-term benefits to patients, as more domestic drugs provide treatment options that align with international standards through solid evidence and reliable quality [3].